The DOI matches its Crossref record; 152 of the 152 references it cites were found in a registry or an index.
Dual roles of Nrf2 in cancer
Open accessAbstract
In response to oxidative stress, the transcription factor NF-E2-related factor 2 (Nrf2) controls the fate of cells through transcriptional upregulation of antioxidant response element (ARE)-bearing genes, including those encoding endogenous antioxidants, phase II detoxifying enzymes, and transporters. Expression of the Nrf2-dependent proteins is critical for ameliorating or eliminating toxicants/carcinogens to maintain cellular redox homeostasis. As a result, activation of the Nrf2 pathway, by naturally-occurring compounds or synthetic chemicals at sub-toxic doses, confers protection against subsequent toxic/carcinogenic exposure. Thus, the use of dietary compounds or synthetic chemicals to boost the Nrf2-dependent adaptive response to counteract environmental insults has emerged to be a promising strategy for cancer prevention. Interestingly, recent emerging data has revealed the “dark” side of Nrf2. Nrf2 and its downstream genes are overexpressed in many cancer cell lines and human cancer tissues, giving cancer cells an advantage for survival and growth. Furthermore, Nrf2 is upregulated in resistant cancer cells and is thought to be responsible for acquired chemoresistance. Therefore, it may be necessary to inhibit the Nrf2 pathway during chemotherapy. This review is primarily focused on the role of Nrf2 in cancer, with emphasis on the recent findings indicating the cancer promoting function of Nrf2 and its role in acquired chemoresistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Nuclear Import and Export Signals in Control of Nrf2
Jain, A. K., Bloom, D. A., & Jaiswal, A. K. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m502083200 · Cited by 195
RetractedItoh, K., Wakabayashi, N., Katoh, Y., Ishii, T., Igarashi, K., Engel, J. D., & Yamamoto, M. (1999) · Genes & Development · doi:10.1101/gad.13.1.76 · Cited by 3,634 · cited 1×
“[5] Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD, et al.”
BackgroundHayes, J. D., Flanagan, J. U., & Jowsey, I. R. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095857 · Cited by 3,544
Mechanisms Underlying Ubiquitination
Pickart, C. M. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.503 · Cited by 3,184
Kobayashi, A., Kang, M.-I., Okawa, H., Ohtsuji, M., Zenke, Y., Chiba, T., Igarashi, K., & Yamamoto, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.16.7130-7139.2004 · Cited by 2,224
Dinkova-Kostova, A. T., Holtzclaw, W. D., Cole, R. N., Itoh, K., Wakabayashi, N., Katoh, Y., Yamamoto, M., & Talalay, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398899 · Cited by 1,947
UBIQUITIN-DEPENDENT PROTEIN DEGRADATION
Hochstrasser, M. (1996) · Annual Review of Genetics · doi:10.1146/annurev.genet.30.1.405 · Cited by 1,692
Moi, P., Chan, K., Asunis, I., Cao, A., & Kan, Y. W. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.21.9926 · Cited by 1,607 · cited 2×
“first cloned and characterized NF-E2-related factor 2 (Nrf2) based on its ability to bind the NF-E2/AP-1 repeat in the promoter of the beta-globin gene [1].”
BackgroundZhang, D. D., & Hannink, M. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.22.8137-8151.2003 · Cited by 1,480 · cited 2×
“Interestingly, we have shown that in cells cotransfected ith Keap1-C151, tBHQ or SF could no longer repress ubiquitinaion of Nrf2 and had no effect on the half-life of Nrf2 [4,40].”
BackgroundSelf-citationRushmore, T. H., Morton, M. R., & Pickett, C. B. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)99004-6 · Cited by 1,464
Cited by
Oxidative stress, inflammation, and cancer: How are they linked?
Reuter, S., Gupta, S. C., Chaturvedi, M. M., & Aggarwal, B. B. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.09.006 · Cited by 5,441
Combination therapy in combating cancer
Mokhtari, R. B., Homayouni, T. S., Baluch, N., Morgatskaya, E., Kumar, S., Das, B., & Yeger, H. (2017) · Oncotarget · doi:10.18632/oncotarget.16723 · Cited by 2,543
Brigelius-Flohé, R., & Maiorino, M. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2012.11.020 · Cited by 1,904
The emerging role of the Nrf2–Keap1 signaling pathway in cancer
Jaramillo, M. C., & Zhang, D. D. (2013) · Genes & Development · doi:10.1101/gad.225680.113 · Cited by 1,297
Self-citationThe development of the concept of ferroptosis
Hirschhorn, T., & Stockwell, B. R. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.09.043 · Cited by 1,052
Valavanidis, A., Vlachogianni, T., Fiotakis, K., & Loridas, S. (2013) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph10093886 · Cited by 910
Lau, A., Wang, X.-J., Zhao, F., Villeneuve, N. F., Wu, T., Jiang, T., Sun, Z., White, E., & Zhang, D. D. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.00248-10 · Cited by 849
Self-citationOxidative Stress and Lipid Peroxidation Products in Cancer Progression and Therapy
Barrera, G. (2012) · ISRN Oncology · doi:10.5402/2012/137289 · Cited by 820
Stress-activated cap’n’collar transcription factors in aging and human disease
Sykiotis, G. P., & Bohmann, D. (2010) · Science Signaling · doi:10.1126/scisignal.3112re3 · Cited by 776
Natural compounds for cancer treatment and prevention
Nobili, S., Lippi, D., Witort, E., Donnini, M., Bausi, L., Mini, E., & Capaccioli, S. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.01.017 · Cited by 780
Allostery in Disease and in Drug Discovery
Nussinov, R., & Tsai, C.-J. (2013) · Cell · doi:10.1016/j.cell.2013.03.034 · Cited by 761
Small Molecule Modulators of Keap1‐ Nrf2‐ ARE Pathway as Potential Preventive and Therapeutic Agents
Magesh, S., Chen, Y., & Hu, L. (2012) · Medicinal Research Reviews · doi:10.1002/med.21257 · Cited by 760
The Roles of NRF2 in Modulating Cellular Iron Homeostasis
Kerins, M. J., & Ooi, A. (2018) · Antioxidants & Redox Signaling · doi:10.1089/ars.2017.7176 · Cited by 738
Tu, W., Wang, H., Li, S., Liu, Q., & Sha, H. (2019) · Aging and disease · doi:10.14336/ad.2018.0513 · Cited by 707
Nrf2-Keap1 pathway promotes cell proliferation and diminishes ferroptosis
Fan, Z., Wirth, A.-K., Chen, D., Wruck, C. J., Rauh, M., Buchfelder, M., & Savaskan, N. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.65 · Cited by 692
Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism
Ren, D., Villeneuve, N. F., Jiang, T., Wu, T., Lau, A., Toppin, H. A., & Zhang, D. D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014275108 · Cited by 673
Self-citationDirect Interaction between Nrf2 and p21Cip1/WAF1 Upregulates the Nrf2-Mediated Antioxidant Response
Chen, W., Sun, Z., Wang, X.-J., Jiang, T., Huang, Z., Fang, D., & Zhang, D. D. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.04.029 · Cited by 638
Self-citationp62 links autophagy and Nrf2 signaling
Jiang, T., Harder, B., Rojo de la Vega, M., Wong, P. K., Chapman, E., & Zhang, D. D. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.06.014 · Cited by 639
Self-citationThe Dual Roles of NRF2 in Cancer
Menegon, S., Columbano, A., & Giordano, S. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.05.002 · Cited by 633
Basic Principles and Emerging Concepts in the Redox Control of Transcription Factors
Brigelius-Flohé, R., & Flohé, L. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3534 · Cited by 576
Hydrogen peroxide – production, fate and role in redox signaling of tumor cells
Lennicke, C., Rahn, J., Lichtenfels, R., Wessjohann, L. A., & Seliger, B. (2015) · Cell Communication and Signaling · doi:10.1186/s12964-015-0118-6 · Cited by 571
Identification of novel NRF2-regulated genes by ChIP-Seq: influence on retinoid X receptor alpha
Chorley, B. N., Campbell, M. R., Wang, X., Karaca, M., Sambandan, D., Bangura, F., Xue, P., Pi, J., Kleeberger, S. R., & Bell, D. A. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks409 · Cited by 558
Therapeutic Potential of Nrf2 Activators in Streptozotocin-Induced Diabetic Nephropathy
Zheng, H., Whitman, S. A., Wu, W., Wondrak, G. T., Wong, P. K., Fang, D., & Zhang, D. D. (2011) · Diabetes · doi:10.2337/db11-0807 · Cited by 507
Self-citationOxidative stress and oxidative damage in chemical carcinogenesis
Klaunig, J. E., Wang, Z., Pu, X., & Zhou, S. (2011) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.11.028 · Cited by 470
Redox-Directed Cancer Therapeutics: Molecular Mechanisms and Opportunities
Wondrak, G. T. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2541 · Cited by 462
The complexity of the Nrf2 pathway: beyond the antioxidant response
Huang, Y., Li, W., Su, Z.-Y., & Kong, A.-N. T. (2015) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2015.08.001 · Cited by 445
Solis, L. M., Behrens, C., Dong, W., Suraokar, M., Ozburn, N. C., Moran, C. A., Corvalan, A. H., Biswal, S., Swisher, S. G., Bekele, B. N., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3352 · Cited by 428
Villeneuve, N. F., Lau, A., & Zhang, D. D. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3211 · Cited by 423
Self-citationOncometabolites: linking altered metabolism with cancer
Yang, M., Soga, T., & Pollard, P. J. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67228 · Cited by 422
Ooi, A., Wong, J.-C., Petillo, D., Roossien, D., Perrier-Trudova, V., Whitten, D., Min, B. W. H., Tan, M.-H., Zhang, Z., Yang, X. J., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.08.024 · Cited by 401
Deshmukh, P., Unni, S., Krishnappa, G., & Padmanabhan, B. (2017) · Biophysical Reviews · doi:10.1007/s12551-016-0244-4 · Cited by 398
Canonical and non-canonical mechanisms of Nrf2 activation
Silva-Islas, C. A., & Maldonado, P. D. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.06.013 · Cited by 388
Triterpenoids as new promising anticancer drugs
Petronelli, A., Pannitteri, G., & Testa, U. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328330fd90 · Cited by 381
Autophagy in liver diseases: Time for translation?
Allaire, M., Rautou, P.-E., Codogno, P., & Lotersztajn, S. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.01.026 · Cited by 378
Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin
Kim, Y. R., Oh, J. E., Kim, M. S., Kang, M. R., Park, S. W., Han, J. Y., Eom, H. S., Yoo, N. J., & Lee, S. H. (2010) · The Journal of Pathology · doi:10.1002/path.2653 · Cited by 358
Natural product-derived pharmacological modulators of Nrf2/ARE pathway for chronic diseases
Kumar, H., Kim, I.-S., More, S. V., Kim, B.-W., & Choi, D.-K. (2014) · Nat. Prod. Rep. · doi:10.1039/c3np70065h · Cited by 333
Arlt, A., Sebens, S., Krebs, S., Geismann, C., Grossmann, M., Kruse, M.-L., Schreiber, S., & Schäfer, H. (2013) · Oncogene · doi:10.1038/onc.2012.493 · Cited by 330
Interrelation of immunity and tissue repair or regeneration
Eming, S. A., Hammerschmidt, M., Krieg, T., & Roers, A. (2009) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2009.04.009 · Cited by 321
Protective effect of sulforaphane against oxidative stress: Recent advances
Guerrero-Beltrán, C. E., Calderón-Oliver, M., Pedraza-Chaverri, J., & Chirino, Y. I. (2012) · Experimental and Toxicologic Pathology · doi:10.1016/j.etp.2010.11.005 · Cited by 320
Glutathione peroxidases in different stages of carcinogenesis
Brigelius-Flohé, R., & Kipp, A. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2009.03.006 · Cited by 305
The Nrf2/Keap1/ARE Pathway and Oxidative Stress as a Therapeutic Target in Type II Diabetes Mellitus
David, J. A., Rifkin, W. J., Rabbani, P. S., & Ceradini, D. J. (2017) · Journal of Diabetes Research · doi:10.1155/2017/4826724 · Cited by 301
Formation and signaling actions of electrophilic lipids
Schopfer, F. J., Cipollina, C., & Freeman, B. A. (2011) · Chemical Reviews · doi:10.1021/cr200131e · Cited by 299
The Nrf2/HO‐1 Axis in Cancer Cell Growth and Chemoresistance
Furfaro, A. L., Traverso, N., Domenicotti, C., Piras, S., Moretta, L., Marinari, U. M., Pronzato, M. A., & Nitti, M. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/1958174 · Cited by 295
Singh, S., Vrishni, S., Singh, B. K., Rahman, I., & Kakkar, P. (2010) · Free Radical Research · doi:10.3109/10715762.2010.507670 · Cited by 293
NRF2 Blockade Suppresses Colon Tumor Angiogenesis by Inhibiting Hypoxia-Induced Activation of HIF-1α
Kim, T.-H., Hur, E.-G., Kang, S.-J., Kim, J.-A., Thapa, D., Lee, Y. M., Ku, S. K., Jung, Y., & Kwak, M.-K. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3007 · Cited by 292
Oncogenic KRAS Confers Chemoresistance by Upregulating NRF2
Tao, S., Wang, S., Moghaddam, S. J., Ooi, A., Chapman, E., Wong, P. K., & Zhang, D. D. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1439 · Cited by 291
Self-citationHigh Levels of Nrf2 Determine Chemoresistance in Type II Endometrial Cancer
Jiang, T., Chen, N., Zhao, F., Wang, X.-J., Kong, B., Zheng, W., & Zhang, D. D. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0713 · Cited by 286
Oxidative stress and metal carcinogenesis
Lee, J.-C., Son, Y.-O., Pratheeshkumar, P., & Shi, X. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.06.002 · Cited by 275
Nrf2 promotes the development of fibrosis and tumorigenesis in mice with defective hepatic autophagy
Ni, H.-M., Woolbright, B. L., Williams, J., Copple, B., Cui, W., Luyendyk, J. P., Jaeschke, H., & Ding, W.-X. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.04.043 · Cited by 270
Mitochondrial Quality Control as a Therapeutic Target
Suliman, H. B., & Piantadosi, C. A. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011502 · Cited by 264
Protein damage, repair and proteolysis
Chondrogianni, N., Petropoulos, I., Grimm, S., Georgila, K., Catalgol, B., Friguet, B., Grune, T., & Gonos, E. S. (2014) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.09.001 · Cited by 256
Nuclear erythroid factor 2-mediated proteasome activation delays senescence in human fibroblasts
Kapeta, S., Chondrogianni, N., & Gonos, E. S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.031575 · Cited by 234
The NEDD8 Conjugation Pathway and Its Relevance in Cancer Biology and Therapy
Soucy, T. A., Dick, L. R., Smith, P. G., Milhollen, M. A., & Brownell, J. E. (2010) · Genes & Cancer · doi:10.1177/1947601910382898 · Cited by 225
Jian, Z., Li, K., Liu, L., Zhang, Y., Zhou, Z., Li, C., & Gao, T. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.56 · Cited by 175
Ju, H.-Q., Gocho, T., Aguilar, M., Wu, M., Zhuang, Z.-N., Fu, J., Yanaga, K., Huang, P., & Chiao, P. J. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0420 · Cited by 137
Role of p62/SQSTM1 in liver physiology and pathogenesis
Manley, S., Williams, J. A., & Ding, W.-X. (2013) · Experimental Biology and Medicine · doi:10.1177/1535370213489446 · Cited by 135
Policastro, L. L., Ibañez, I. L., Notcovich, C., Duran, H. A., & Podhajcer, O. L. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4367 · Cited by 120
Hartikainen, J. M., Tengström, M., Kosma, V.-M., Kinnula, V. L., Mannermaa, A., & Soini, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1474 · Cited by 89
Karihtala, P., Kauppila, S., Soini, Y., & Arja-Jukkola-Vuorinen (2011) · BMC Cancer · doi:10.1186/1471-2407-11-262 · Cited by 87
NRF2 immunolocalization in human breast cancer patients as a prognostic factor
Onodera, Y., Motohashi, H., Takagi, K., Miki, Y., Shibahara, Y., Watanabe, M., Ishida, T., Hirakawa, H., Sasano, H., Yamamoto, M., et al. (2014) · Endocrine-Related Cancer · doi:10.1530/erc-13-0234 · Cited by 81
Nrf2-mediated redox signaling in arsenic carcinogenesis: a review
Sinha, D., Biswas, J., & Bishayee, A. (2013) · Archives of Toxicology · doi:10.1007/s00204-012-0920-5 · Cited by 81
Tkaczenko, H., & Kurhaluk, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031098 · Cited by 80
Oxidative Stress-Related Mechanisms in Melanoma and in the Acquired Resistance to Targeted Therapies
Pizzimenti, S., Ribero, S., Cucci, M. A., Grattarola, M., Monge, C., Dianzani, C., Barrera, G., & Muzio, G. (2021) · Antioxidants · doi:10.3390/antiox10121942 · Cited by 79
Rojo de la Vega, M., Krajisnik, A., Zhang, D., & Wondrak, G. (2017) · Nutrients · doi:10.3390/nu9121371 · Cited by 77
Self-citationReduction of DNA damage induced by titanium dioxide nanoparticles through Nrf2 in vitro and in vivo
Shi, Z., Niu, Y., Wang, Q., Shi, L., Guo, H., Liu, Y., Zhu, Y., Liu, S., Liu, C., Chen, X., et al. (2015) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2015.05.043 · Cited by 56
Skin Redox Balance Maintenance: The Need for an Nrf2-Activator Delivery System
Ben-Yehuda Greenwald, M., Ben-Sasson, S., Bianco-Peled, H., & Kohen, R. (2016) · Cosmetics · doi:10.3390/cosmetics3010001 · Cited by 49
Kim, Y. H., Coon, A., Baker, A. F., & Powis, G. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1500-0 · Cited by 45
Al Saihati, H. A., Badr, O. A., Dessouky, A. A., Mostafa, O., Samir Farid, A., Aborayah, N. H., Abdullah Aljasir, M., Baioumy, B., Mahmoud Taha, N., El-Sherbiny, M., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112934 · Cited by 17
Metadata
- Authors
- LAU, A., VILLENEUVE, N., SUN, Z., WONG, P., & ZHANG, D.
- Venue
- Pharmacological Research
- Publisher
- Elsevier BV
- Published
- 2008-11
- Volume
- 58
- Issue
- 5-6
- Pages
- 262-270
- ISSN
- 1043-6618 (ISSN-L)
- OpenAlex
- W2059378857
- Cited by
- 645
- References
- 152
- FWCI
- 13.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.